These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25655769)

  • 1. Recombinant porcine factor VIII: a new installment of a long story.
    Mannucci PM
    Haemophilia; 2015 Mar; 21(2):149-151. PubMed ID: 25655769
    [No Abstract]   [Full Text] [Related]  

  • 2. Interpreting data on inhibitor development from previously untreated patient studies, beware of premature conclusions.
    Fischer K
    Haemophilia; 2018 Mar; 24(2):177-179. PubMed ID: 29537122
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant factor VIII in hemophilia.
    Cohen A; Butler R
    N Engl J Med; 1991 May; 324(21):1515-6. PubMed ID: 1902552
    [No Abstract]   [Full Text] [Related]  

  • 4. Porcine factor VIII.
    Giangrande PL
    Haemophilia; 2012 May; 18(3):305-9. PubMed ID: 22531020
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII.
    Bray G
    Ann Hematol; 1994; 68 Suppl 3():S29-34. PubMed ID: 8180254
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.
    Kruse-Jarres R; St-Louis J; Greist A; Shapiro A; Smith H; Chowdary P; Drebes A; Gomperts E; Bourgeois C; Mo M; Novack A; Farin H; Ewenstein B
    Haemophilia; 2015 Mar; 21(2):162-170. PubMed ID: 25623166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor VIIa and factor VIII treatment for acquired factor VIII deficiency: a case of repeated thrombotic endotracheal occlusion in a mechanically ventilated patient.
    Lauer S; Westphal M; Fischer LG; Meissner A; Van Aken H; Freise H
    Crit Care; 2011; 15(2):407. PubMed ID: 21418550
    [No Abstract]   [Full Text] [Related]  

  • 8. After the SIPPET study: Position paper of the CoMETH, the French society of haemophilia.
    Lebreton A; Castet S; Falaise C; Rugeri L; Schved JF; Wibaut B
    Haemophilia; 2018 Mar; 24(2):e55-e57. PubMed ID: 29316084
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of acquired haemophilia with recombinant porcine factor VIII: A successful strategy in a patient with unstable angina.
    Owen M; Gidley G; Horn EH
    Haemophilia; 2019 Mar; 25(2):e94-e97. PubMed ID: 30604899
    [No Abstract]   [Full Text] [Related]  

  • 10. Transient inhibitors in the Recombinate PUP study.
    Rothschild C; Gill J; Scharrer I; Bray G
    Thromb Haemost; 2000 Jul; 84(1):145-6. PubMed ID: 10928491
    [No Abstract]   [Full Text] [Related]  

  • 11. Summary of clinical experience with recombinant factor VIII products--Recombinate.
    White GC
    Ann Hematol; 1994; 68 Suppl 3():S7-8. PubMed ID: 8180260
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary and secondary ethical issues arising from the introduction of recombinant factor VIII: "primum non nocere," but what next?
    McDonald M
    Transfus Med Rev; 1992 Oct; 6(4):271-6. PubMed ID: 1421828
    [No Abstract]   [Full Text] [Related]  

  • 13. Additional antihemophilic factor to be available.
    Thompson CA
    Am J Health Syst Pharm; 2008 Apr; 65(7):592. PubMed ID: 18359961
    [No Abstract]   [Full Text] [Related]  

  • 14. Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.
    Mannucci PM; Franchini M
    Blood Transfus; 2017 Jul; 15(4):365-368. PubMed ID: 27483484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected pharmacokinetics of recombinant porcine factor VIII in a patient with acquired factor VIII deficiency and spontaneous epidural haematoma.
    Shatzel JJ; Azar S; Scherber R; Gay N; Deloughery TG; VanSandt A; Kruse-Jarres R; Recht M; Taylor JA
    Haemophilia; 2017 Sep; 23(5):e453-e456. PubMed ID: 28664642
    [No Abstract]   [Full Text] [Related]  

  • 16. International Symposium on Recombinant Factor VIII: report of the proceedings.
    Growe GH; Poon MC; Scarth I
    Transfus Med Rev; 1992 Apr; 6(2):137-45. PubMed ID: 1591490
    [No Abstract]   [Full Text] [Related]  

  • 17. The current status of recombinant human factor VIII.
    Aronson DL
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):55-6. PubMed ID: 1908131
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute left anterior descending artery occlusion in a hemophiliac A patient during recombinant factor VIII infusion: treatment with coronary angioplasty.
    Alsolaiman MM; Chang K; Arjomand H; Oza R; Costacurta G
    Catheter Cardiovasc Interv; 2000 Aug; 50(4):468-72. PubMed ID: 10931624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who should use recombinant factor VIII?
    Hoots K
    Ann Hematol; 1994; 68 Suppl 3():S65-8. PubMed ID: 8180258
    [No Abstract]   [Full Text] [Related]  

  • 20. FVIII dosages in persons with haemophilia A treated with extended half-life products: From local biology to optimized patient management.
    Perrier-Cornet A; Philippe A; Lambert T; d'Oiron R; Rafowicz A; Lavenu-Bombled C; Combe S; Gillibert A; Proulle V
    Haemophilia; 2019 Nov; 25(6):e361-e363. PubMed ID: 31206947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.